According to the recent research, there are over 80% of people would be motivated to exercise if incentivized by crypto...

Cryptocurrency

Recent Study Reveals That Crypto Motivates People to Exercise

On Friday, Prime Minister Ranil Wickremesinghe warned of a food shortage as the island nation battles a devastating economic...

Economy

Thousands queue for petrol, gas in Sri Lanka amid warnings of food shortages

ASML, a semiconductor industry and stock market giant, might have to think smaller. Or maybe bigger. Currently, it is building machines...

Technology

Computer chip giant ASML places big bets on a tiny future

Finance ministers and central bank governors of the United States, Japan, Canada, Britain, Germany, France and Italy - the G7, agreed on...

Economy

Money for Ukraine Priority in G7 Agenda; Inflation, Food a Concern

An auto safety agency in the U.S. said on Wednesday that it has opened an investigation into a fatal crash involving a Tesla...

Stock Markets

U.S. Agency opens investigation involving Tesla due to 14 Crash Deaths

World

8 Mar 2022

Moderna Prepares for Future Pandemic through Human Vaccine Trials against 15 Viruses

Moderna Prepares for Future Pandemic through Human Vaccine Trials against 15 Viruses

The Index Today

Moderna Inc. is gearing up to start human trials for vaccines against 15 highly infectious viruses and their pathogens by 2025.

This program has been instituted to develop vaccines against a wide array of contagious viruses in order to avert another potential pandemic in the future. It comes amid recent criticism against Moderna by activists for not supplying vaccine doses to poor countries soon enough.

As per a statement by Moderna, their agenda involves creating archetypal vaccines against viruses responsible for causing the Middle East Respiratory Syndrome, Ebola, Marburg infection, as well as dengue fever and chikungunya.

According to Bloomberg News, the company has already started human vaccine trials against key viruses, namely the Zika and HIV viruses. The development for the vaccine against Nipah is also underway.

In a statement, Moderna’s CEO Stephane Bancel said, “Since our beginning, we have focused on developing a global health vaccine program. Today, we are renewing that focus by expanding our work to develop vaccines against priority pathogens that threaten global health.”